Tristel plc
("Tristel" or the "Company")
Confirmation of interim results
Investor presentation
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, confirms that its interim results for the six months ended 31 December 2022 will be announced on Monday 20 February 2023.
Analyst briefing
A briefing open to analysts will take place in London on Monday 20 February 2023 at 9.30am. To register and for more details please contact Walbrook PR on tristel@walbrookpr.com
Investor presentation
Paul Swinney, CEO, and Liz Dixon, CFO, will provide a live hybrid presentation relating to the Company's interim results on Monday 20 February 2023 at 4:30pm, which is open to all existing and potential shareholders.
For those attending in-person, the Company welcome them to 85 Gresham Street, London, EC2V 7NQ from 4.15pm for a 4.30pm start and will be followed by refreshments.
For those that are unable to attend, a live webcast of the investor briefing will be broadcast.
If you would like to register to attend in-person, or require the link for the live webcast, please contact Walbrook PR on 020 7933 8787 or email tristel@walbrookpr.com, ensuring you detail in your email if you will attend in-person or online.
The results presentation will be made available on the Company's website on the day of results - www.tristelgroup.com
For further information please contact:
Tristel plc | Tel: 01638 721 500 | |
Paul Swinney, Chief Executive Officer | | |
Liz Dixon, Chief Financial Officer | | |
| | |
Walbrook PR Ltd | Tel: 020 7933 8780 or tristel@walbrookpr.com | |
Paul McManus | Mob: 07980 541 893 | |
Lianne Applegarth | Mob: 07584 391 303 | |
| | |
finnCap | Tel: 020 7220 0500 | |
Geoff Nash/ Charles Beeson (Corporate Finance) | | |
Alice Lane (ECM) | | |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.